(Q38031633)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22857533%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22857533%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22857533%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Caterina Fattorusso

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22857533%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Manuela Rodriquez

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22857533%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Giuseppe Giannini

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22857533%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

1 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22857533%20AND%20SRC:MED&resulttype=core&format=json

Future Medicinal Chemistry

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22857533%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22857533%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22857533%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

1439-1460

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22857533%20AND%20SRC:MED&resulttype=core&format=json

ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS

9 February 2020

cites work

1 reference

Identification of a gene encoding a yeast histone H4 acetyltransferase

21 January 2018

1 reference

Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation

21 January 2018

1 reference

A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p

21 January 2018

1 reference

Silent information regulator 2 family of NAD- dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose

21 January 2018

1 reference

Class IIa histone deacetylases: regulating the regulators

21 January 2018

1 reference

21 January 2018

1 reference

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

21 January 2018

1 reference

Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

21 January 2018

1 reference

Epigenetics--an epicenter of gene regulation: histones and histone-modifying enzymes

21 January 2018

1 reference

Histone deacetylation in epigenetics: an attractive target for anticancer therapy

21 January 2018

1 reference

Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors.

21 January 2018

1 reference

Histone deacetylase inhibitors in the treatment of hematological malignancies.

21 January 2018

1 reference

Histone modification enzymes: novel targets for cancer drugs

21 January 2018

1 reference

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

21 January 2018

1 reference

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

21 January 2018

1 reference

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

21 January 2018

1 reference

Class II histone deacetylases: from sequence to function, regulation, and clinical implication

21 January 2018

1 reference

Acetylation and deacetylation of non-histone proteins

21 January 2018

1 reference

Substrate and functional diversity of lysine acetylation revealed by a proteomics survey

21 January 2018

1 reference

HDAC family: What are the cancer relevant targets?

21 January 2018

1 reference

Histone deacetylase inhibitors: overview and perspectives

21 January 2018

1 reference

Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development

21 January 2018

1 reference

Cardiac histone acetylation--therapeutic opportunities abound

21 January 2018

1 reference

Toward transcriptional therapies for the failing heart: chemical screens to modulate genes

21 January 2018

1 reference

Histone deacetylases: silencers for hire.

21 January 2018

1 reference

Regulating histone acetyltransferases and deacetylases

21 January 2018

1 reference

E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex

21 January 2018

1 reference

Pocket protein complexes are recruited to distinct targets in quiescent and proliferating cells

21 January 2018

1 reference

Sin meets NuRD and other tails of repression.

21 January 2018

1 reference

Corepressor-dependent silencing of chromosomal regions encoding neuronal genes

21 January 2018

1 reference

Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR

21 January 2018

1 reference

Functional characterization of an amino-terminal region of HDAC4 that possesses MEF2 binding and transcriptional repressive activity

21 January 2018

1 reference

Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo

21 January 2018

1 reference

Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases

21 January 2018

1 reference

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

21 January 2018

1 reference

Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain

21 January 2018

1 reference

Role of histone deacetylases and their inhibitors in cancer biology and treatment.

21 January 2018

1 reference

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

21 January 2018

1 reference

HDAC expression and clinical prognosis in human malignancies

21 January 2018

1 reference

Differential protein acetylation induced by novel histone deacetylase inhibitors

21 January 2018

1 reference

Inside HDAC with HDAC inhibitors

21 January 2018

1 reference

3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment

21 January 2018

1 reference

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

21 January 2018

1 reference

A new group of potent inducers of differentiation in murine erythroleukemia cells

21 January 2018

1 reference

Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity

21 January 2018

1 reference

Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.

21 January 2018

1 reference

Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.

21 January 2018

1 reference

N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors

21 January 2018

1 reference

Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.

21 January 2018

1 reference

Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities

21 January 2018

1 reference

N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

21 January 2018

1 reference

Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase

21 January 2018

1 reference

Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal alpha-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities.

21 January 2018

1 reference

Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1.

21 January 2018

1 reference

Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 2.

21 January 2018

1 reference

Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222.

21 January 2018

1 reference

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives

21 January 2018

1 reference

(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.

21 January 2018

1 reference

Trifluoromethyl ketones as inhibitors of histone deacetylase

21 January 2018

1 reference

Heterocyclic ketones as inhibitors of histone deacetylase.

21 January 2018

1 reference

Azetidinones as zinc-binding groups to design selective HDAC8 inhibitors

21 January 2018

1 reference

Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.

21 January 2018

1 reference

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines

21 January 2018

1 reference

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

Regulation of p53 responses by post-translational modifications

21 January 2018

1 reference

Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation

21 January 2018

1 reference

RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD.

21 January 2018

1 reference

The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis

21 January 2018

1 reference

Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5.

21 January 2018

1 reference

Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line

21 January 2018

1 reference

Histone deacetylase inhibitors specifically kill nonproliferating tumour cells

21 January 2018

1 reference

Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis

21 January 2018

1 reference

Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

21 January 2018

1 reference

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.

21 January 2018

1 reference

Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status.

21 January 2018

1 reference

Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1.

21 January 2018

1 reference

Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1.

21 January 2018

1 reference

Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor

21 January 2018

1 reference

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

Clinical development of histone deacetylase inhibitors as anticancer agents

21 January 2018

1 reference

Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects

21 January 2018

1 reference

Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases

21 January 2018

1 reference

Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents

21 January 2018

1 reference

Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin.

21 January 2018

1 reference

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

Targeting tumor angiogenesis with histone deacetylase inhibitors

21 January 2018

1 reference

Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation

21 January 2018

1 reference

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

21 January 2018

1 reference

Effects of histone deacetylase inhibitors on HIF-1

21 January 2018

1 reference

Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha

21 January 2018

1 reference

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

21 January 2018

1 reference

Downregulation of hypoxia-related responses by novel antitumor histone deacetylase inhibitors in MDAMB231 breast cancer cells.

21 January 2018

1 reference

Anti-invasive activity of histone deacetylase inhibitors via the induction of Egr-1 and the modulation of tight junction-related proteins in human hepatocarcinoma cells

21 January 2018

1 reference

Epigenetics, nervous system tumors, and cancer stem cells

21 January 2018

1 reference

Histone deacetylase inhibitors: Potential in cancer therapy

21 January 2018

1 reference

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

21 January 2018

1 reference

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.

21 January 2018

1 reference

New patented histone deacetylase inhibitors

21 January 2018

1 reference

Explorative study on isoform-selective histone deacetylase inhibitors

21 January 2018

1 reference

Histone deacetylase inhibitors: current status and overview of recent clinical trials

21 January 2018

1 reference

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

21 January 2018

1 reference

Predictive biomarkers: a paradigm shift towards personalized cancer medicine

21 January 2018

1 reference

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis

21 January 2018

1 reference

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

21 January 2018

1 reference

HDAC inhibitors as anti-inflammatory agents

21 January 2018

1 reference

Valproic acid: a potential role in treating latent HIV infection

21 January 2018

1 reference

HDAC inhibitors in parasitic diseases

21 January 2018

1 reference

Recovery of learning and memory is associated with chromatin remodelling

21 January 2018

1 reference

Multiple roles of HDAC inhibition in neurodegenerative conditions.

21 January 2018

1 reference

Histone deacetylase inhibitors as therapeutics for polyglutamine disorders

21 January 2018

1 reference

Hydroxamide derivatives of short-chain fatty acid have erythropoietic activity and induce gamma gene expression in vivo

21 January 2018

1 reference

Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors.

21 January 2018

1 reference

Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.

21 January 2018

1 reference

Pharmacological modulation of stem cell function.

21 January 2018

1 reference

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

21 January 2018

1 reference

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference